Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study

Thomas Idorn; Filip K Knop; Morten Jørgensen; Tonny Jensen; Marsela Resuli; Pernille M Hansen; Karl Christensen; Jens Juul Holst; Mads Hornum; Bo Feldt-Rasmussen

doi:10.1136/bmjopen-2013-002764

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study

Thomas Idorn, Filip K Knop, Morten Jørgensen, Tonny Jensen, Marsela Resuli, Pernille M Hansen, Karl Christensen, Jens Juul Holst, Mads Hornum, Bo Feldt-Rasmussen

13 Citations (Scopus)

Abstract

Diabetes is the leading cause of end-stage renal disease (ESRD). Owing to renal clearance, several antidiabetic agents cannot be used in patients with ESRD. The present protocol describes an investigator-initiated trial aiming to test safety and efficacy of treatment with the glucagon-like peptide-1 receptor agonist liraglutide in patients with type 2 diabetes and dialysis-dependent ESRD.

Original language	English
Article number	e002764
Journal	BMJ Open
Volume	3
Issue number	4
Number of pages	10
DOIs	https://doi.org/10.1136/bmjopen-2013-002764
Publication status	Published - 26 Apr 2013

Access to Document

10.1136/bmjopen-2013-002764

Fingerprint

Dive into the research topics of 'Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study'. Together they form a unique fingerprint.

Cite this

Idorn, T., Knop, F. K., Jørgensen, M., Jensen, T., Resuli, M., Hansen, P. M., Christensen, K., Holst, J. J., Hornum, M., & Feldt-Rasmussen, B. (2013). Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open, 3(4), Article e002764. https://doi.org/10.1136/bmjopen-2013-002764

Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. / Idorn, Thomas; Knop, Filip K; Jørgensen, Morten et al.
In: BMJ Open, Vol. 3, No. 4, e002764, 26.04.2013.

Research output: Contribution to journal › Journal article › Research › peer-review

Idorn, T, Knop, FK, Jørgensen, M, Jensen, T, Resuli, M, Hansen, PM, Christensen, K, Holst, JJ, Hornum, M & Feldt-Rasmussen, B 2013, 'Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study', BMJ Open, vol. 3, no. 4, e002764. https://doi.org/10.1136/bmjopen-2013-002764

@article{4ee98b508913432badf475cda374e7b8,

title = "Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study",

abstract = "Diabetes is the leading cause of end-stage renal disease (ESRD). Owing to renal clearance, several antidiabetic agents cannot be used in patients with ESRD. The present protocol describes an investigator-initiated trial aiming to test safety and efficacy of treatment with the glucagon-like peptide-1 receptor agonist liraglutide in patients with type 2 diabetes and dialysis-dependent ESRD.",

author = "Thomas Idorn and Knop, {Filip K} and Morten J{\o}rgensen and Tonny Jensen and Marsela Resuli and Hansen, {Pernille M} and Karl Christensen and Holst, {Jens Juul} and Mads Hornum and Bo Feldt-Rasmussen",

year = "2013",

month = apr,

day = "26",

doi = "10.1136/bmjopen-2013-002764",

language = "English",

volume = "3",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group Ltd",

number = "4",

}

TY - JOUR

T1 - Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease

T2 - protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study

AU - Idorn, Thomas

AU - Knop, Filip K

AU - Jørgensen, Morten

AU - Jensen, Tonny

AU - Resuli, Marsela

AU - Hansen, Pernille M

AU - Christensen, Karl

AU - Holst, Jens Juul

AU - Hornum, Mads

AU - Feldt-Rasmussen, Bo

PY - 2013/4/26

Y1 - 2013/4/26

N2 - Diabetes is the leading cause of end-stage renal disease (ESRD). Owing to renal clearance, several antidiabetic agents cannot be used in patients with ESRD. The present protocol describes an investigator-initiated trial aiming to test safety and efficacy of treatment with the glucagon-like peptide-1 receptor agonist liraglutide in patients with type 2 diabetes and dialysis-dependent ESRD.

AB - Diabetes is the leading cause of end-stage renal disease (ESRD). Owing to renal clearance, several antidiabetic agents cannot be used in patients with ESRD. The present protocol describes an investigator-initiated trial aiming to test safety and efficacy of treatment with the glucagon-like peptide-1 receptor agonist liraglutide in patients with type 2 diabetes and dialysis-dependent ESRD.

U2 - 10.1136/bmjopen-2013-002764

DO - 10.1136/bmjopen-2013-002764

M3 - Journal article

C2 - 23624993

SN - 2044-6055

VL - 3

JO - BMJ Open

JF - BMJ Open

IS - 4

M1 - e002764

ER -